Contraception Selection, Effectiveness, and Adverse Effects: A Review
Many women spend a substantial proportion of their lives preventing or planning for pregnancy, and approximately 87% of US women use contraception during their lifetime. Contraceptive effectiveness is determined by a combination of drug or device efficacy, individual fecundability, coital frequency,...
Uloženo v:
| Vydáno v: | JAMA : the journal of the American Medical Association Ročník 326; číslo 24; s. 2507 |
|---|---|
| Hlavní autoři: | , |
| Médium: | Journal Article |
| Jazyk: | angličtina |
| Vydáno: |
United States
28.12.2021
|
| Témata: | |
| ISSN: | 1538-3598, 1538-3598 |
| On-line přístup: | Zjistit podrobnosti o přístupu |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
|
| Abstract | Many women spend a substantial proportion of their lives preventing or planning for pregnancy, and approximately 87% of US women use contraception during their lifetime.
Contraceptive effectiveness is determined by a combination of drug or device efficacy, individual fecundability, coital frequency, and user adherence and continuation. In the US, oral contraceptive pills are the most commonly used reversible method of contraception and comprise 21.9% of all contraception in current use. Pregnancy rates of women using oral contraceptives are 4% to 7% per year. Use of long-acting methods, such as intrauterine devices and subdermal implants, has increased substantially, from 6% of all contraceptive users in 2008 to 17.8% in 2016; these methods have failure rates of less than 1% per year. Estrogen-containing methods, such as combined oral contraceptive pills, increase the risk of venous thrombosis from 2 to 10 venous thrombotic events per 10 000 women-years to 7 to 10 venous thrombotic events per 10 000 women-years, whereas progestin-only and nonhormonal methods, such as implants and condoms, are associated with rare serious risks. Hormonal contraceptives can improve medical conditions associated with hormonal changes related to the menstrual cycle, such as acne, endometriosis, and premenstrual dysphoric disorder. Optimal contraceptive selection requires patient and clinician discussion of the patient's tolerance for risk of pregnancy, menstrual bleeding changes, other risks, and personal values and preferences.
Oral contraceptive pills are the most commonly used reversible contraceptives, intrauterine devices and subdermal implants have the highest effectiveness, and progestin-only and nonhormonal methods have the lowest risks. Optimal contraceptive selection incorporates patient values and preferences. |
|---|---|
| AbstractList | Many women spend a substantial proportion of their lives preventing or planning for pregnancy, and approximately 87% of US women use contraception during their lifetime.
Contraceptive effectiveness is determined by a combination of drug or device efficacy, individual fecundability, coital frequency, and user adherence and continuation. In the US, oral contraceptive pills are the most commonly used reversible method of contraception and comprise 21.9% of all contraception in current use. Pregnancy rates of women using oral contraceptives are 4% to 7% per year. Use of long-acting methods, such as intrauterine devices and subdermal implants, has increased substantially, from 6% of all contraceptive users in 2008 to 17.8% in 2016; these methods have failure rates of less than 1% per year. Estrogen-containing methods, such as combined oral contraceptive pills, increase the risk of venous thrombosis from 2 to 10 venous thrombotic events per 10 000 women-years to 7 to 10 venous thrombotic events per 10 000 women-years, whereas progestin-only and nonhormonal methods, such as implants and condoms, are associated with rare serious risks. Hormonal contraceptives can improve medical conditions associated with hormonal changes related to the menstrual cycle, such as acne, endometriosis, and premenstrual dysphoric disorder. Optimal contraceptive selection requires patient and clinician discussion of the patient's tolerance for risk of pregnancy, menstrual bleeding changes, other risks, and personal values and preferences.
Oral contraceptive pills are the most commonly used reversible contraceptives, intrauterine devices and subdermal implants have the highest effectiveness, and progestin-only and nonhormonal methods have the lowest risks. Optimal contraceptive selection incorporates patient values and preferences. Many women spend a substantial proportion of their lives preventing or planning for pregnancy, and approximately 87% of US women use contraception during their lifetime.IMPORTANCEMany women spend a substantial proportion of their lives preventing or planning for pregnancy, and approximately 87% of US women use contraception during their lifetime.Contraceptive effectiveness is determined by a combination of drug or device efficacy, individual fecundability, coital frequency, and user adherence and continuation. In the US, oral contraceptive pills are the most commonly used reversible method of contraception and comprise 21.9% of all contraception in current use. Pregnancy rates of women using oral contraceptives are 4% to 7% per year. Use of long-acting methods, such as intrauterine devices and subdermal implants, has increased substantially, from 6% of all contraceptive users in 2008 to 17.8% in 2016; these methods have failure rates of less than 1% per year. Estrogen-containing methods, such as combined oral contraceptive pills, increase the risk of venous thrombosis from 2 to 10 venous thrombotic events per 10 000 women-years to 7 to 10 venous thrombotic events per 10 000 women-years, whereas progestin-only and nonhormonal methods, such as implants and condoms, are associated with rare serious risks. Hormonal contraceptives can improve medical conditions associated with hormonal changes related to the menstrual cycle, such as acne, endometriosis, and premenstrual dysphoric disorder. Optimal contraceptive selection requires patient and clinician discussion of the patient's tolerance for risk of pregnancy, menstrual bleeding changes, other risks, and personal values and preferences.OBSERVATIONSContraceptive effectiveness is determined by a combination of drug or device efficacy, individual fecundability, coital frequency, and user adherence and continuation. In the US, oral contraceptive pills are the most commonly used reversible method of contraception and comprise 21.9% of all contraception in current use. Pregnancy rates of women using oral contraceptives are 4% to 7% per year. Use of long-acting methods, such as intrauterine devices and subdermal implants, has increased substantially, from 6% of all contraceptive users in 2008 to 17.8% in 2016; these methods have failure rates of less than 1% per year. Estrogen-containing methods, such as combined oral contraceptive pills, increase the risk of venous thrombosis from 2 to 10 venous thrombotic events per 10 000 women-years to 7 to 10 venous thrombotic events per 10 000 women-years, whereas progestin-only and nonhormonal methods, such as implants and condoms, are associated with rare serious risks. Hormonal contraceptives can improve medical conditions associated with hormonal changes related to the menstrual cycle, such as acne, endometriosis, and premenstrual dysphoric disorder. Optimal contraceptive selection requires patient and clinician discussion of the patient's tolerance for risk of pregnancy, menstrual bleeding changes, other risks, and personal values and preferences.Oral contraceptive pills are the most commonly used reversible contraceptives, intrauterine devices and subdermal implants have the highest effectiveness, and progestin-only and nonhormonal methods have the lowest risks. Optimal contraceptive selection incorporates patient values and preferences.CONCLUSIONS AND RELEVANCEOral contraceptive pills are the most commonly used reversible contraceptives, intrauterine devices and subdermal implants have the highest effectiveness, and progestin-only and nonhormonal methods have the lowest risks. Optimal contraceptive selection incorporates patient values and preferences. |
| Author | Teal, Stephanie Edelman, Alison |
| Author_xml | – sequence: 1 givenname: Stephanie surname: Teal fullname: Teal, Stephanie organization: Department of OB/GYN, University Hospitals Medical Center and Case Western Reserve University, Cleveland, Ohio – sequence: 2 givenname: Alison surname: Edelman fullname: Edelman, Alison organization: Department of OB/GYN, Oregon Health & Science University, Portland |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/34962522$$D View this record in MEDLINE/PubMed |
| BookMark | eNpNj8tLw0AYxBep2IeevUmOHpq4--1ud-OtlPqAguDjHL50v0BKsqnZpOJ_b4oVnMv8YIaBmbKRbzwxdi14IjgXdzusMQEOIgEhUzhjE6GljaVO7egfj9k0hB0fJKS5YGOp0gVogAlbrxrftbilfVc2PnqjirZHmkfrojjigTyFMI_Qu2jpDtQGOkXhPlpGr3Qo6euSnRdYBbo6-Yx9PKzfV0_x5uXxebXcxCiV6mKkgnLSEo1ytjBWOyW1gdxpTXxhNQHSEIlcaWNUnuYFOQDlOCIaqSzM2O3v7r5tPnsKXVaXYUtVhZ6aPmSwEFrw1Fo-VG9O1T6vyWX7tqyx_c7-rsMPxatcjQ |
| CitedBy_id | crossref_primary_10_1016_j_yjpso_2024_100132 crossref_primary_10_3390_nu16203490 crossref_primary_10_1007_s00404_024_07413_5 crossref_primary_10_1097_og9_0000000000000003 crossref_primary_10_1186_s12905_023_02561_3 crossref_primary_10_1016_j_ejogrb_2025_114540 crossref_primary_10_1093_ofid_ofae125 crossref_primary_10_2147_IJWH_S377418 crossref_primary_10_3389_fphar_2024_1486422 crossref_primary_10_1210_endrev_bnaf016 crossref_primary_10_1016_S2352_3026_23_00059_5 crossref_primary_10_1007_s12170_022_00705_y crossref_primary_10_1186_s12905_024_03172_2 crossref_primary_10_1016_j_pop_2024_12_008 crossref_primary_10_1016_j_ejogrb_2024_07_048 crossref_primary_10_3390_bs14090829 crossref_primary_10_1007_s00404_025_08050_2 crossref_primary_10_1001_jama_2022_2857 crossref_primary_10_1007_s40265_022_01738_8 crossref_primary_10_1001_jama_2022_2854 crossref_primary_10_37521_ejpps30213 crossref_primary_10_62347_GVKI9955 crossref_primary_10_1038_s41598_025_09604_9 crossref_primary_10_1016_j_saa_2024_124541 crossref_primary_10_1016_j_ajog_2024_04_039 crossref_primary_10_1080_07391102_2024_2330714 crossref_primary_10_1016_j_contraception_2022_02_013 crossref_primary_10_1186_s12978_025_02074_2 crossref_primary_10_14797_mdcvj_1313 crossref_primary_10_1136_bmj_2024_083874 crossref_primary_10_1080_03007995_2025_2472907 crossref_primary_10_1016_j_asjsur_2024_01_082 crossref_primary_10_31382_preprint_000103 crossref_primary_10_1016_j_jadohealth_2024_09_004 crossref_primary_10_1111_bjhp_12788 crossref_primary_10_1210_clinem_dgae374 crossref_primary_10_1111_odi_70044 crossref_primary_10_1177_17407745241264217 crossref_primary_10_1016_j_pdisas_2024_100368 crossref_primary_10_1186_s40834_025_00350_x crossref_primary_10_1371_journal_pone_0282147 crossref_primary_10_3390_cancers15123163 crossref_primary_10_1002_alz_70610 crossref_primary_10_1016_j_midw_2025_104362 crossref_primary_10_1093_inthealth_ihaf053 crossref_primary_10_2196_63683 crossref_primary_10_1089_ham_2024_0021 crossref_primary_10_1186_s12889_025_21427_x crossref_primary_10_1055_a_1835_8808 crossref_primary_10_1177_17455057241256919 crossref_primary_10_1002_ijgo_70548 crossref_primary_10_1016_S2352_3018_25_00048_7 crossref_primary_10_1016_j_jpag_2023_06_003 crossref_primary_10_1016_j_colsurfb_2022_112893 crossref_primary_10_1111_andr_13525 crossref_primary_10_1007_s00246_025_03791_y crossref_primary_10_1089_whr_2023_0185 crossref_primary_10_1038_s42004_025_01427_z crossref_primary_10_3390_jcm14072188 crossref_primary_10_1016_j_jtherbio_2023_103741 crossref_primary_10_1089_jwh_2023_0857 crossref_primary_10_1016_j_ejmech_2022_114898 crossref_primary_10_1016_j_actbio_2025_08_007 crossref_primary_10_1016_j_contraception_2025_110860 crossref_primary_10_1016_j_fbio_2024_105666 crossref_primary_10_1080_09513590_2023_2247093 crossref_primary_10_1038_s41598_023_41365_1 crossref_primary_10_1016_j_tiv_2024_105782 crossref_primary_10_1016_j_yhbeh_2025_105725 crossref_primary_10_1007_s40290_025_00555_0 crossref_primary_10_1093_ofid_ofae337 crossref_primary_10_1016_j_nurpra_2022_11_001 crossref_primary_10_1080_13625187_2022_2107199 crossref_primary_10_1186_s12933_023_01966_6 crossref_primary_10_1016_j_yfrne_2022_101016 crossref_primary_10_1002_ccr3_70737 crossref_primary_10_1016_S0140_6736_22_00627_4 crossref_primary_10_1080_14728214_2023_2296080 crossref_primary_10_1016_j_colsurfb_2023_113633 crossref_primary_10_1016_j_jddst_2024_105357 crossref_primary_10_1016_S0140_6736_23_02800_3 crossref_primary_10_1186_s40834_023_00243_x crossref_primary_10_7759_cureus_30582 crossref_primary_10_7759_cureus_84642 crossref_primary_10_1096_fj_202201258R crossref_primary_10_1136_bjsports_2022_106519 crossref_primary_10_3389_fgwh_2024_1395863 crossref_primary_10_1001_jama_2022_11541 crossref_primary_10_5694_mja2_52451 crossref_primary_10_7326_M23_0788 crossref_primary_10_3390_jcm12144791 crossref_primary_10_1186_s12905_024_03004_3 crossref_primary_10_3897_pharmacia_72_e140451 crossref_primary_10_1016_j_socscimed_2023_116081 crossref_primary_10_1038_s41598_024_64753_7 crossref_primary_10_1161_STROKEAHA_124_048869 crossref_primary_10_1007_s12088_024_01226_5 crossref_primary_10_1007_s11886_024_02033_6 crossref_primary_10_1016_j_thromres_2022_09_013 crossref_primary_10_1080_13697137_2024_2404574 crossref_primary_10_1007_s40279_024_02074_5 crossref_primary_10_1016_j_contraception_2024_110781 crossref_primary_10_1186_s12958_025_01421_z crossref_primary_10_1007_s10620_024_08836_5 crossref_primary_10_1002_ijgo_15567 crossref_primary_10_3389_ijph_2023_1605564 crossref_primary_10_1371_journal_pone_0304221 crossref_primary_10_1071_PY22212 crossref_primary_10_1002_pbc_31683 crossref_primary_10_1002_rfc2_35 crossref_primary_10_1016_j_arthro_2025_02_012 crossref_primary_10_1016_j_annonc_2024_10_824 crossref_primary_10_1016_j_nurpra_2024_105164 crossref_primary_10_1097_ACO_0000000000001397 crossref_primary_10_1126_science_adq6656 crossref_primary_10_11124_JBIES_23_00170 crossref_primary_10_1123_wspaj_2024_0016 crossref_primary_10_26538_tjnpr_v9i7_63 crossref_primary_10_1016_j_vetpar_2024_110330 crossref_primary_10_1007_s10654_025_01236_7 crossref_primary_10_1080_03630242_2024_2447603 crossref_primary_10_1097_MD_0000000000037843 crossref_primary_10_1016_j_ogc_2024_02_008 crossref_primary_10_3390_ijms25169037 crossref_primary_10_3390_jcm13020575 crossref_primary_10_1097_MD_0000000000043721 crossref_primary_10_1007_s13669_025_00423_3 crossref_primary_10_1016_j_bpobgyn_2024_102571 crossref_primary_10_1016_j_contraception_2025_110816 crossref_primary_10_3390_pharmaceutics16081030 crossref_primary_10_1007_s12609_024_00534_5 crossref_primary_10_1016_j_neurot_2025_e00620 crossref_primary_10_1080_09513590_2023_2254400 crossref_primary_10_1056_EVIDoa2400480 crossref_primary_10_3389_fphar_2024_1491032 crossref_primary_10_1080_17425255_2023_2279752 crossref_primary_10_1016_j_yebeh_2024_110154 crossref_primary_10_1016_j_jconrel_2025_113858 crossref_primary_10_1016_j_rcsop_2025_100591 crossref_primary_10_1080_07853890_2024_2370568 crossref_primary_10_1080_09687637_2023_2261614 crossref_primary_10_3390_ijerph20020965 crossref_primary_10_3389_frph_2025_1576265 crossref_primary_10_1097_GME_0000000000002191 crossref_primary_10_1007_s11684_023_1051_5 crossref_primary_10_1016_j_whi_2025_02_009 crossref_primary_10_1016_j_contraception_2023_110064 crossref_primary_10_52872_001c_126659 crossref_primary_10_1523_JNEUROSCI_1235_24_2024 crossref_primary_10_1186_s13048_023_01296_x crossref_primary_10_1016_j_nurpra_2022_08_006 crossref_primary_10_1371_journal_pone_0319928 crossref_primary_10_1093_ejendo_lvad082 crossref_primary_10_2147_OAJC_S444545 crossref_primary_10_1016_j_thromres_2025_109279 crossref_primary_10_1371_journal_pone_0301207 crossref_primary_10_1111_ejh_70014 crossref_primary_10_1038_s41443_025_01114_6 crossref_primary_10_1016_j_contraception_2025_110944 |
| ContentType | Journal Article |
| DBID | CGR CUY CVF ECM EIF NPM 7X8 |
| DOI | 10.1001/jama.2021.21392 |
| DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic |
| DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | no_fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1538-3598 |
| ExternalDocumentID | 34962522 |
| Genre | Journal Article Review |
| GroupedDBID | --- -ET -~X .55 .XZ 0R~ 0WA 186 18M 29J 2CT 2FS 2KS 2WC 354 39C 4.4 53G 5GY 5RE 6TJ 85S AAIKC AAMNW AAQQT AAWTL ABBLC ABCQX ABEHJ ABIVO ABOCM ABPMR ABPPZ ABRSH ABWJO ACAHW ACGFS ACNCT ACPRK ACQAM ADBBV ADUKH ADXHL AFCHL AFFNX AFRAH AGHSJ AHMBA ALMA_UNASSIGNED_HOLDINGS AMJDE ANMPU ARBJA BKOMP BRYMA C45 CGR CJ0 CS3 CUY CVF EAM EBD EBS ECM EIF EJD EMOBN EX3 F5P H13 HF~ KOO KQ8 L7B MVM N4W N9A NEJ NPM OBH OCB OGEVE OHH OMK OVD P2P PQQKQ RAJ RNS SJN SV3 TEORI TN5 UHB UKR UPT VVN WH7 WOW X7M XHN XSW XZL YFH YOC YPV YQT YQY YR2 YR5 YSK YYM YZZ ZCA ~H1 7X8 |
| ID | FETCH-LOGICAL-a344t-aefebe53a74d8f785d43572bd55e0685e2ae74d1b45774b9bfed224d0aaa73482 |
| IEDL.DBID | 7X8 |
| ISICitedReferencesCount | 191 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000739785000023&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 1538-3598 |
| IngestDate | Thu Oct 02 05:08:10 EDT 2025 Mon Jul 21 05:45:15 EDT 2025 |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 24 |
| Language | English |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-a344t-aefebe53a74d8f785d43572bd55e0685e2ae74d1b45774b9bfed224d0aaa73482 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 ObjectType-Review-3 content type line 23 |
| PMID | 34962522 |
| PQID | 2615109880 |
| PQPubID | 23479 |
| ParticipantIDs | proquest_miscellaneous_2615109880 pubmed_primary_34962522 |
| PublicationCentury | 2000 |
| PublicationDate | 2021-Dec-28 20211228 |
| PublicationDateYYYYMMDD | 2021-12-28 |
| PublicationDate_xml | – month: 12 year: 2021 text: 2021-Dec-28 day: 28 |
| PublicationDecade | 2020 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States |
| PublicationTitle | JAMA : the journal of the American Medical Association |
| PublicationTitleAlternate | JAMA |
| PublicationYear | 2021 |
| References | 35438734 - JAMA. 2022 Apr 19;327(15):1504 |
| References_xml | – reference: 35438734 - JAMA. 2022 Apr 19;327(15):1504 |
| SSID | ssj0000137 |
| Score | 2.686241 |
| SecondaryResourceType | review_article |
| Snippet | Many women spend a substantial proportion of their lives preventing or planning for pregnancy, and approximately 87% of US women use contraception during their... |
| SourceID | proquest pubmed |
| SourceType | Aggregation Database Index Database |
| StartPage | 2507 |
| SubjectTerms | Contraception - adverse effects Contraception - methods Contraceptive Agents - adverse effects Contraceptive Devices Contraceptives, Oral Contraindications Female Humans Male |
| Title | Contraception Selection, Effectiveness, and Adverse Effects: A Review |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/34962522 https://www.proquest.com/docview/2615109880 |
| Volume | 326 |
| WOSCitedRecordID | wos000739785000023&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1LSwMxEA5qRbz4ftQXETw2uJtNNlkvUqTFS0tBhd6WZJOAl23tVn-_k2xKvQiCl7AQAstkMvMlM3wfQndCaJroihNLC0aYVJIooxXJqoRLC4iZ5a3YhBiP5XRaTOKDWxPbKlcxMQRqM6v8G_k99ak3KcDdHucfxKtG-epqlNDYRJ0MoIz3ajGVP-ijAmdmONSeqW5F7bNmHaJwRYSF9Hd8GfLMcP-_f3iA9iLCxP3WJQ7Rhq2P0M4o1tCP0cATUi1UbGfBL0EIB756uGUyjuGvh1VtcNBrbmycah5wH7fVhBP0Nhy8Pj2TKKZAVMbYkijrYL94pgQz0gnJDQAlQbXh3Ca55JYqC1OpZhwQoS60swbSu0mUUoEB5xRt1bPaniNsPLu5S2ylWc5cWskEUJlwVrk0z60ouuh2ZaASnNVXIFRtZ59NuTZRF521Vi7nLatG6ZnrKaDBiz-svkS7fu98WwmVV6jj4Kjaa7RdfS3fm8VN8AIYx5PRN9eAu2k |
| linkProvider | ProQuest |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Contraception+Selection%2C+Effectiveness%2C+and+Adverse+Effects%3A+A+Review&rft.jtitle=JAMA+%3A+the+journal+of+the+American+Medical+Association&rft.au=Teal%2C+Stephanie&rft.au=Edelman%2C+Alison&rft.date=2021-12-28&rft.eissn=1538-3598&rft.volume=326&rft.issue=24&rft.spage=2507&rft_id=info:doi/10.1001%2Fjama.2021.21392&rft_id=info%3Apmid%2F34962522&rft_id=info%3Apmid%2F34962522&rft.externalDocID=34962522 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1538-3598&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1538-3598&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1538-3598&client=summon |